Formulation and optimization of niosomes for topical Diacerein (cas 13739-02-1) delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis
-
Add time:09/28/2019 Source:sciencedirect.com
This research aimed towards the design of preparations of Diacerein (cas 13739-02-1) loaded cholesterol rich niosomes by employing a 3-factor, 3-level Box-Behnken design. Results indicated that Span 60 (90 mg) and cholesterol (10 mg), and 45 min of hydration time were found to be optimum for niosomes preparation. The prepared cholesterol rich niosomes were uniform and spherical in size. Optimized formulation F2 entrapped the drug with 83.02% efficiency in the cholesterol rich niosomes of the size 477.8 nm, presented the flux of 2.820 μg/cm2/h, followed Higuchi model and non Fickian transport mechanism. The confocal laser scanning microscopy showed that niosomes accentuated the penetration of diacerein in the epidermal and dermal layer of rat skin. Stability study confirmed that cholesterol rich niosomes were stable for 2 months at 4 °C. Concisely, the results showed that targeted diacerein delivery might be achieved using topically applied niosomes for enhanced treatment of psoriasis, which might eliminate adverse side effects associated with systemic exposure.
We also recommend Trading Suppliers and Manufacturers of Diacerein (cas 13739-02-1). Pls Click Website Link as below: cas 13739-02-1 suppliers
Prev:Original articleDiacerein (cas 13739-02-1) orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial
Next:Pharmacological treatment with Diacerein (cas 13739-02-1) combined with mechanical stimulation affects the expression of growth factors in human chondrocytes) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pharmacological treatment with Diacerein (cas 13739-02-1) combined with mechanical stimulation affects the expression of growth factors in human chondrocytes09/29/2019
- Original articleDiacerein (cas 13739-02-1) orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial10/01/2019
- Original articleDiacerein (cas 13739-02-1) alleviates kidney injury through attenuating inflammation and oxidative stress in obese insulin-resistant rats09/27/2019
- Original ArticleValidated determination of Diacerein (cas 13739-02-1) and its active metabolite, rhein, by stability indicating constant pattern method as a novel manipulation of zero order spectra09/26/2019
- Diacerein (cas 13739-02-1) inhibits Estradiol-benzoate induced cervical hyperkeratosis in female rats09/25/2019
- Mechanical exposure and Diacerein (cas 13739-02-1) treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes09/24/2019
- Diacerein (cas 13739-02-1) protects against glycerol-induced acute kidney injury: Modulating oxidative stress, inflammation, apoptosis and necroptosis09/10/2019
- Novel spectrophotometric methods for the determination of Leflunomide and Diacerein (cas 13739-02-1) in binary mixtures09/09/2019
- Original articlePharmacokinetics and bioequivalence study of rhein as the main metabolite of Diacerein (cas 13739-02-1)09/08/2019